Teva Pharmaceutical Industries Current Ratio 2010-2024 | TEVA
Current and historical current ratio for Teva Pharmaceutical Industries (TEVA) from 2010 to 2024. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations. Teva Pharmaceutical Industries current ratio for the three months ending September 30, 2024 was 0.89.
| Teva Pharmaceutical Industries Current Ratio Historical Data |
| Date |
Current Assets |
Current Liabilities |
Current Ratio |
| 2024-09-30 |
$12.31B |
$13.80B |
0.89 |
| 2024-06-30 |
$11.63B |
$13.04B |
0.89 |
| 2024-03-31 |
$12.30B |
$13.79B |
0.89 |
| 2023-12-31 |
$12.49B |
$12.25B |
1.02 |
| 2023-09-30 |
$11.43B |
$11.39B |
1.00 |
| 2023-06-30 |
$12.09B |
$11.84B |
1.02 |
| 2023-03-31 |
$11.50B |
$10.41B |
1.11 |
| 2022-12-31 |
$12.05B |
$11.47B |
1.05 |
| 2022-09-30 |
$11.45B |
$11.53B |
0.99 |
| 2022-06-30 |
$12.16B |
$11.00B |
1.11 |
| 2022-03-31 |
$12.45B |
$11.61B |
1.07 |
| 2021-12-31 |
$12.57B |
$11.03B |
1.14 |
| 2021-09-30 |
$12.15B |
$11.83B |
1.03 |
| 2021-06-30 |
$12.82B |
$12.69B |
1.01 |
| 2021-03-31 |
$12.40B |
$12.09B |
1.03 |
| 2020-12-31 |
$13.01B |
$13.16B |
0.99 |
| 2020-09-30 |
$12.16B |
$12.10B |
1.01 |
| 2020-06-30 |
$12.78B |
$11.75B |
1.09 |
| 2020-03-31 |
$12.88B |
$12.32B |
1.05 |
| 2019-12-31 |
$13.46B |
$13.67B |
0.99 |
| 2019-09-30 |
$12.54B |
$14.11B |
0.89 |
| 2019-06-30 |
$13.81B |
$14.45B |
0.96 |
| 2019-03-31 |
$13.43B |
$14.03B |
0.96 |
| 2018-12-31 |
$13.79B |
$14.32B |
0.96 |
| 2018-09-30 |
$13.88B |
$14.83B |
0.94 |
| 2018-06-30 |
$14.71B |
$14.22B |
1.04 |
| 2018-03-31 |
$14.69B |
$14.76B |
1.00 |
| 2017-12-31 |
$15.38B |
$17.92B |
0.86 |
| 2017-09-30 |
$16.23B |
$16.94B |
0.96 |
| 2017-06-30 |
$14.60B |
$15.46B |
0.94 |
| 2017-03-31 |
$14.84B |
$15.90B |
0.93 |
| 2016-12-31 |
$17.23B |
$18.49B |
0.93 |
| 2016-09-30 |
$17.39B |
$19.29B |
0.90 |
| 2016-06-30 |
$18.34B |
$14.41B |
1.27 |
| 2016-03-31 |
$16.99B |
$12.91B |
1.32 |
| 2015-12-31 |
$18.40B |
$13.01B |
1.42 |
| 2015-09-30 |
$12.50B |
$12.98B |
0.96 |
| 2015-06-30 |
$13.30B |
$14.47B |
0.92 |
| 2015-03-31 |
$15.71B |
$12.47B |
1.26 |
| 2014-12-31 |
$14.40B |
$12.29B |
1.17 |
| 2014-09-30 |
$13.92B |
$11.67B |
1.19 |
| 2014-06-30 |
$13.55B |
$11.85B |
1.14 |
| 2014-03-31 |
$13.45B |
$11.40B |
1.18 |
| 2013-12-31 |
$13.72B |
$11.97B |
1.15 |
| 2013-09-30 |
$13.91B |
$12.16B |
1.14 |
| 2013-06-30 |
$14.09B |
$12.84B |
1.10 |
| 2013-03-31 |
$14.42B |
$12.36B |
1.17 |
| 2012-12-31 |
$16.36B |
$12.89B |
1.27 |
| 2012-09-30 |
$14.98B |
$10.63B |
1.41 |
| 2012-06-30 |
$14.23B |
$10.01B |
1.42 |
| 2012-03-31 |
$14.97B |
$13.63B |
1.10 |
| 2011-12-31 |
$14.45B |
$13.68B |
1.06 |
| 2011-09-30 |
$13.02B |
$11.48B |
1.13 |
| 2011-06-30 |
$12.60B |
$10.05B |
1.25 |
| 2011-03-31 |
$12.05B |
$8.89B |
1.36 |
| 2010-12-31 |
$12.04B |
$9.69B |
1.24 |
| 2010-09-30 |
$11.86B |
$9.32B |
1.27 |
| 2010-06-30 |
$14.44B |
$8.18B |
1.77 |
| 2010-03-31 |
$12.61B |
$8.34B |
1.51 |
| 2009-12-31 |
$12.14B |
$7.60B |
1.60 |
| 2009-09-30 |
$11.46B |
$7.23B |
1.58 |
| 2009-06-30 |
$11.04B |
$7.24B |
1.52 |
| 2009-03-31 |
$11.14B |
$8.57B |
1.30 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$19.044B |
$15.846B |
|
Teva Pharmaceutical Industries Limited is a global pharmaceutical company that develops, manufactures, and markets both branded and generic drugs, as well as active pharmaceutical ingredients in North America, Europe, Latin America, India, and Israel. Teva's generic product portfolio includes tablets, capsules, liquids, ointments, creams, liquids, injectables, and inhalants. The company's branded products include Copaxone, Austedo, respiratory products like ProAir and Qvar and Ajovy. Teva operates through three segments, North America, Europe and International Markets, each of which includes generics, specialty and over-the-counter products. Teva acquired Allergan's generics business Actavis Generics. The company also acquired Allergan's Anda Inc. Teva acquired Auspex Pharmaceuticals and Barr. Teva has strengthened its position in Europe through its acquisition of Germany's second largest generics producer, ratiopharm.
|
